NASDAQ:CDLX • US14161W1053
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CARDLYTICS INC (CDLX).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-08-08 | Evercore ISI Group | Maintains | In-Line -> In-Line |
| 2025-05-08 | Lake Street | Maintains | Hold -> Hold |
| 2025-03-13 | Lake Street | Maintains | Hold -> Hold |
| 2025-03-13 | Needham | Reiterate | Hold -> Hold |
| 2025-03-13 | Evercore ISI Group | Maintains | In-Line -> In-Line |
| 2025-01-17 | Needham | Reiterate | Hold -> Hold |
| 2024-11-07 | Needham | Reiterate | Hold |
| 2024-10-11 | Evercore ISI Group | Initiate | In-Line |
| 2024-08-16 | Northland Capital Markets | Downgrade | Outperform -> Market Perform |
| 2024-08-15 | B of A Securities | Downgrade | Neutral -> Underperform |
| 2024-08-08 | Lake Street | Downgrade | Buy -> Hold |
| 2024-08-08 | Needham | Downgrade | Buy -> Hold |
| 2024-08-08 | Northland Capital Markets | Maintains | Outperform -> Outperform |
| 2024-06-20 | B of A Securities | Reiterate | Neutral |
| 2024-06-18 | Northland Capital Markets | Initiate | Outperform |
| 2024-06-11 | Needham | Reiterate | Buy -> Buy |
| 2024-05-09 | Needham | Maintains | Buy -> Buy |
| 2024-05-09 | Craig-Hallum | Maintains | Buy -> Buy |
| 2024-04-09 | Needham | Maintains | Buy -> Buy |
| 2024-03-15 | Lake Street | Maintains | Buy -> Buy |
| 2024-03-15 | Needham | Maintains | Buy -> Buy |
| 2024-03-15 | Craig-Hallum | Upgrade | Hold -> Buy |
| 2024-01-30 | Needham | Reiterate | Buy -> Buy |
| 2023-11-29 | Lake Street | Initiate | Buy |
| 2023-11-09 | Needham | Maintains | Buy -> Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|
| Revenue YoY % growth | 309.204M 3.59% | 278.298M -10.00% | 233.273M -16.18% | 164.57M -29.45% | 179.09M 8.82% | |
| EBITDA YoY % growth | -40.455M -211.32% | -38.054M 5.93% | -21.999M 42.19% | 17.354M 178.89% | 30.294M 74.56% | |
| EBIT YoY % growth | -66.915M -5,476.25% | -63.743M 4.74% | -47.243M 25.89% | -31.749M 32.80% | -20.293M 36.08% | |
| Operating Margin | -21.64% | -22.90% | -20.25% | -19.29% | -11.33% | |
| EPS YoY % growth | -0.34 81.32% | -0.39 -14.71% | -0.38 2.56% | -0.32 16.79% | 0.05 116.13% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.22 -3.62% | -0.17 -28.15% | -0.12 -74.86% | -0.08 -383.32% | -0.14 34.37% | -0.13 20.41% | -0.08 33.33% | -0.04 52.00% |
| Revenue Q2Q % growth | 37.944M -38.70% | 38.27M -39.49% | 40.774M -21.64% | 45.017M -19.75% | 43.554M 14.78% | 46.308M 21.00% | 52.326M 28.33% | 59.058M 31.19% |
| EBITDA Q2Q % growth | -5.83M 55.62% | -2.553M -11,000.26% | -283.223K -103.03% | 1.896M -90.38% | 714K 112.25% | 1.326M 151.94% | 3.876M 1,468.53% | 6.222M 228.16% |
| EBIT Q2Q % growth | -11.606M 40.27% | -8.972M 28.73% | -6.643M 31.45% | -4.494M 18.78% | -5.916M 49.03% | -5.202M 42.02% | -2.652M 60.08% | -408K 90.92% |
All data in USD
10 analysts have analysed CDLX and the average price target is 1.06 USD. This implies a price increase of 18.06% is expected in the next year compared to the current price of 0.8964.
CARDLYTICS INC (CDLX) will report earnings on 2026-05-05.
The consensus EPS estimate for the next earnings of CARDLYTICS INC (CDLX) is -0.22 USD and the consensus revenue estimate is 37.94M USD.
The consensus rating for CARDLYTICS INC (CDLX) is 48 / 100 . This indicates that analysts generally have a neutral outlook on the stock.